Moomoo AI 已提取核心信息
On February 27, 2024, Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. The announcement was made through a press release and included updates on the company's business operations and pipeline progress. Recursion reported a net loss of $93.0 million for the fourth quarter and $328.1 million for the fiscal year. Despite the losses, the company highlighted several key developments, including the progress of multiple clinical programs expected to provide Phase 2 data in the second half of 2024 and the first half of 2025, and the in-licensing of a novel program for treating fibrotic diseases. Recursion also emphasized its integration of causal AI models into its operating system, following a data partnership...Show More
On February 27, 2024, Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. The announcement was made through a press release and included updates on the company's business operations and pipeline progress. Recursion reported a net loss of $93.0 million for the fourth quarter and $328.1 million for the fiscal year. Despite the losses, the company highlighted several key developments, including the progress of multiple clinical programs expected to provide Phase 2 data in the second half of 2024 and the first half of 2025, and the in-licensing of a novel program for treating fibrotic diseases. Recursion also emphasized its integration of causal AI models into its operating system, following a data partnership with Tempus. The company's cash and cash equivalents stood at $391.6 million as of December 31, 2023. Additionally, Recursion announced an updated investor presentation and a presentation made in connection with its L(earnings) call, both of which were released on the same day as the financial results. The company uses various channels, including SEC filings, its investor relations website, press releases, public conference calls, webcasts, and social media, to communicate with investors and the public.
2024年2月27日,临床阶段的TechBio公司Recursion Pharmicals, Inc. 公布了截至2023年12月31日的第四季度和财年的财务业绩。该公告是通过新闻稿发布的,其中包括公司业务运营和管道进展的最新情况。Recursion报告称,第四季度净亏损9,300万美元,本财年净亏损3.281亿美元。尽管出现亏损,但该公司还是强调了几项关键进展,包括预计将在2024年下半年和2025年上半年提供2期数据的多个临床项目的进展,以及一项治疗纤维化疾病的新计划的许可。在与Tempus建立数据合作关系之后,Recursion还强调将因果人工智能模型集成到其操作系统中。截至2023年1...展开全部
2024年2月27日,临床阶段的TechBio公司Recursion Pharmicals, Inc. 公布了截至2023年12月31日的第四季度和财年的财务业绩。该公告是通过新闻稿发布的,其中包括公司业务运营和管道进展的最新情况。Recursion报告称,第四季度净亏损9,300万美元,本财年净亏损3.281亿美元。尽管出现亏损,但该公司还是强调了几项关键进展,包括预计将在2024年下半年和2025年上半年提供2期数据的多个临床项目的进展,以及一项治疗纤维化疾病的新计划的许可。在与Tempus建立数据合作关系之后,Recursion还强调将因果人工智能模型集成到其操作系统中。截至2023年12月31日,该公司的现金及现金等价物为3.916亿美元。此外,Recursion还宣布了最新的投资者演示文稿和与L(收益)电话会议相关的演示文稿,两者均与财务业绩同日发布。该公司使用各种渠道与投资者和公众沟通,包括美国证券交易委员会的文件、其投资者关系网站、新闻稿、公开电话会议、网络直播和社交媒体。
有用
没用